Press Releases

19 May 2022

Closing of the acquisition of Specific Diagnostics

13 May 2022

bioMérieux announces the CE marking of VIDAS® tests for Chikungunya virus diagnosis

04 May 2022

bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel

12 Apr 2022

Specific Diagnostics acquisition

11 Apr 2022

First-Quarter 2022 Business Review

18 Mar 2022

bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system

02 Mar 2022

bioMérieux – 2021 Financial Results

17 Feb 2022

MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics

06 Jan 2022

French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance

14 Dec 2021

Corporate Social Responsibility: bioMérieux recently received a series of official recognitions from independent third parties

10 Dec 2021

bioMérieux – Increased outlook for full-year 2021

01 Dec 2021

bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant

21 Oct 2021

Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury

21 Oct 2021

bioMérieux – Third-Quarter 2021 Business Review

13 Sep 2021

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

What are you looking for?

Closing of the acquisition of Specific Diagnostics

bioMérieux announces the CE marking of VIDAS® tests for Chikungunya virus diagnosis

bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel

Specific Diagnostics acquisition

First-Quarter 2022 Business Review

bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system

bioMérieux – 2021 Financial Results

MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics

French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance

Corporate Social Responsibility: bioMérieux recently received a series of official recognitions from independent third parties

bioMérieux – Increased outlook for full-year 2021

bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant

Baxter and bioMérieux announce CE mark for NEPHROCLEAR™ CCL14 test to predict persistent severe acute kidney injury

bioMérieux – Third-Quarter 2021 Business Review

A survey in 5 European countries about sepsis demonstrates the lack of awareness and an expectation for faster diagnostic capabilities

Company

Other Websites

Adjust Your Preferences